.jpg)
1 hour ago
3
Article content
HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health (“NIH”), in connection with the Company’s contract supporting development of the VXV-01 fungal vaccine candidate.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Article content
The notice relates to contract number 75N93025C00033, which was awarded in October 2025. The five–year contract consists of a base period and twelve option periods, of which a 22-month base period of performance totalling US$3.6 million had been awarded. Appili is currently assessing the scope and potential implications of this notice.
Article content
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
The Company remains focused on maximizing value from ATI-1801, its Priority Review Voucher (“PRV”) eligible program targeting cutaneous leishmaniasis. As a late-stage asset with a well-defined development pathway, ATI-1801 represents a key opportunity for both near-term value creation and potential PRV monetization. The Company is actively pursuing discussions to support the next stage of development and advance the program towards the clinic.
Article content
Appili continues to benefit from its commercial portfolio through royalty revenue generated by LIKMEZ®, reinforcing its commitment to building sustainable revenue. The Company continues to evaluate strategic collaborations and non-dilutive funding opportunities that leverage its infectious disease expertise.
Article content
Article content
Update on Non-dilutive Funding Proposals
Article content
Appili continues to pursue non-dilutive funding to support its infectious disease and biodefense pipeline. The Company has been awarded more than US$75 million in cumulative government funding since inception and remains actively engaged in additional non-dilutive funding proposals.
Article content
Management believes this focused strategy positions the Company to efficiently deploy capital while advancing opportunities capable of generating meaningful long-term shareholder value. Appili remains committed to its mission of developing and commercializing products that address important unmet needs in infectious diseases while maintaining a disciplined approach to capital allocation.
Article content
About Appili Therapeutics
Article content
Appili Therapeutics is a biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial resistant infections, a vaccine candidate to prevent tularemia, a serious biological weapon threat, and a topical antiparasitic for the treatment of cutaneous leishmaniasis, a disfiguring disease. Led by a proven management team, Appili is at the center of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.
English (US)